Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SOLESENCE, INC. Director's Dealing 2007

Jul 2, 2007

33563_dirs_2007-07-02_1e86be6f-7517-4609-8b8f-a9fdbd66421d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NANOPHASE TECHNOLOGIES CORPORATION (NANX)
CIK: 0000883107
Period of Report: 2007-07-02

Reporting Person: PERKINS DONALD S (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2007-07-02 Deferred Common Stock $ A 979 Acquired Common Stock (979) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 42144 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (right to buy) $3.50 2008-10-29 Common Stock (25000) 20000 Direct
Stock Option (right to buy) $5.25 2008-06-10 Common Stock (2000) 667 Direct
Stock Option (right to buy) $5.75 2008-02-19 Common Stock (10000) 3334 Direct
Stock Option (right to buy) $1.75 2009-07-27 Common Stock (10000) 6667 Direct
Stock Option (right to buy) $9.92 2011-06-05 Common Stock (2000) 2000 Direct
Stock Option (right to buy) $3.78 2012-11-25 Common Stock (2000) 2000 Direct
Stock Option (right to buy) $5.07 2013-06-26 Common Stock (2000) 2000 Direct

Footnotes

F1: Subject to certain restrictions, beginning on this date, options vest in five equal installments.

F2: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.

F3: Each share of deferred common stock represents a right to receive one share of common stock.

F4: 979 shares of common stock were to be granted under the Company's 2005 Non-Employee Director Restricted Stock Plan. Such shares are vested immediately but subject to certain transfer restrictions. Pursuant to such plan, the reporting person elected to defer receipt of such shares and receive instead 979 shares of deferred common stock which, along with the 5,773 similar shares granted previously, will be accounted for under the Company's Non-Employee Director Deferred Compensation Plan.

F5: The deferred common stock becomes payable upon the reporting person's termination of service as a director of the Company.

F6: Pursuant to such plan, the reporting person elected to defer receipt of such shares and receive 979 shares of deferred common stock, amounting to a cumulative total of 6,752 shares of deferred common stock received (including those received from previous grants) to date, which will all be accounted for under the Company's Non-Employee Director Deferred Compensation Plan.